Bioatla Inc (BCAB) Stock Price, Quote & News

Company Profile

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma o...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 558 0708

Fax: 858 558 0709

Website: www.bioatla.com

Address:

11085 Torreyana Road, San Diego, United States

Nikoty Apr. 1 at 8:10 PM

$BCAB lol +80%

1 · Reply

TwongStocks Apr. 1 at 5:47 PM

$BCAB Equity Corporate Actions Alert #2026 - 206 Information Regarding the Reverse Stock Split and CUSIP Number Change for BioAtla, Inc. (BCAB) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-206 BioAtla, Inc. (BCAB) will effect a one-for-fifty (1-50) reverse split of its common stock. The reverse stock split will become effective on Monday, April 6, 2026. In conjunction with the reverse split, the CUSIP number will change to 09077B203.

0 · Reply

Patrickweee Apr. 1 at 4:42 PM

$BCAB Patiently wait for the SPV news

0 · Reply

gregwiseman Apr. 1 at 4:21 PM

$BCAB FRAUDOLENT RS the company didnt have the majority to approve the rs so the company gonna be investigated they lied they didnt have the rs approved by by the shareholders. ok lets wait the reply from the sec

0 · Reply

gregwiseman Apr. 1 at 3:38 PM

$BCAB they didn.t have the vast manority of the shareholders to approve the reverse split . How could the rs be approved .i think they are doing fraudolent rs . The approvememt is fake . I sent my claim to the sec asking for investigation .

0 · Reply

biovaluable Apr. 1 at 3:02 PM

$BCAB delisting crisis cause spv deal is not complete until march

0 · Reply

LabPsycho Apr. 1 at 3:02 PM

$BCAB @dudereally As I have been posting for years, I think conditionally active biomolecules have potential and BCAB was the leader but it seems big pharm has gone their own way with similar tech. Ironically, I think the one asset they had with the most potential (was very preliminary when I posted about it several years ago - they licensed to CNTX. Curious to see how that turns out.

1 · Reply

biovaluable Apr. 1 at 1:58 PM

$BCAB chinese scam stock

0 · Reply

LabPsycho Apr. 1 at 1:38 PM

$BCAB For any CEO to state in a quarterly report that they want ‘to maximize shareholder value’ after the Stock is down over 99.9% in ~ 5yr After the implied pending partnership for over 2 years and non-dilutive funding never happened But instead dilutied bigly near historic lows Should feel shame – but they don’t – its all part of the BioGrifter’s Wealth Transfer Over 2 yr ago I posted my concerns here, and at a conference call, analyst R. B. posed the question to Jay – something to the effect of 'have you thought about shelving the whole project ?' should have sent investors scrambling to the door that day. Too bad, I still think conditionally active biomolecules have potential.

0 · Reply

biovaluable Apr. 1 at 1:33 PM

$BCAB fxxx short jay

0 · Reply

BioAtla Announces Share Consolidation

Mar 31, 2026, 4:05 PM EDT - 1 day ago

BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Mar 2, 2026, 7:30 AM EST - 4 weeks ago

BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets

Dec 31, 2025, 7:00 AM EST - 3 months ago

BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

Nov 21, 2025, 12:25 AM EST - 4 months ago

BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

Nov 13, 2025, 4:05 PM EST - 4 months ago

BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

$BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas$

Nov 7, 2025, 9:00 AM EST - 5 months ago

BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

Nov 5, 2025, 8:00 AM EST - 5 months ago

BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025

Oct 23, 2025, 8:00 AM EDT - 5 months ago

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

$BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025$

Oct 20, 2025, 8:00 AM EDT - 5 months ago

BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025

Oct 3, 2025, 9:00 AM EDT - 6 months ago

BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025

Sep 8, 2025, 8:00 AM EDT - 7 months ago

BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA

Aug 7, 2025, 4:05 PM EDT - 8 months ago

BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Aug 4, 2025, 8:00 AM EDT - 8 months ago

BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

Jul 17, 2025, 8:00 AM EDT - 9 months ago

BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting

$BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress$